---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-051727"
form_type: "8-K"
ticker: null
cik: "0001845459"
company_name: "NKGen Biotech, Inc."
filed_at: "2026-05-04T23:59:59+00:00"
generated_at: "2026-05-15T00:01:08.406962+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# NKGen Biotech secures additional $607,200 convertible loan from AlpineBrook; consideration shares increased to 12.0M

## Summary
- Additional loan of $607,200 (net $552,000 after $55,200 facilitation fee) from AlpineBrook Capital.
- New convertible note (Additional Note #1) bears interest at the Applicable Rate, converts at $0.08 per share.
- Consideration shares increased to 12,009,780, issuable in five installments over 25 months.
- Additional warrant issued to AlpineBrook for up to 3x principal/conversion price shares, exercise price $0.08, ten-year term.
- Voting agreement requires shareholders to authorize sufficient common stock for conversion and exercise of warrants.

## SEC filing metadata
- accession: 0001213900-26-051727
- form_type: 8-K
- cik: 0001845459
- company_name: NKGen Biotech, Inc.
- filed_at: 2026-05-04T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1845459/000121390026051727/0001213900-26-051727-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1845459/000121390026051727/ea0288796-8k_nkgen.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-051727
- JSON: https://secwatch.observer/filing/0001213900-26-051727.json
- Plain text: https://secwatch.observer/filing/0001213900-26-051727.txt

## Source-grounded claims
- claim_id: 5d1780fc649c3a3c2b6189cf8aba49305eca0749
  claim: NKGen Biotech, Inc. incurred convertible notes of $607,200 with AlpineBrook Capital GP I Limited at Applicable Rate (as defined in the Loan Agreement) maturing Not explicitly stated beyond the ten-year warrant period.
  evidence_excerpt: and Exchange Commission (the “ SEC ”) on April 21, 2026). Pursuant to the Amendment, the Lender agreed to extend an additional loan to the Borrowers in the principal amount of $607,200 (the “ Additional Loan ”), which includes a facilitation fee of $55,200 that is fully earned by and owed to the Lender on the effective date and is included in the principal
  evidence_url: https://www.sec.gov/Archives/edgar/data/1845459/000121390026051727/0001213900-26-051727-index.htm
- claim_id: 0495aa510a5e3f343d1a31b0dda5edb71e13aaa9
  claim: NKGen Biotech, Inc. amended Omnibus Amendment to Secured Convertible Loan Agreement and Other Loan Documents with AlpineBrook Capital GP I Limited valued at principal amount of $607,200 (effective 2026-04-28).
  evidence_excerpt: On April 28, 2026, NKGen Biotech, Inc., a Delaware corporation (the “ Company ”), and NKGen Operating Biotech, Inc., a Delaware corporation and wholly owned subsidiary of the Company (“ NKGen OpCo ,” and together with the Company, the “ Borrowers ”), entered into an Omnibus Amendment to Secured Convertible Loan Agreement and Other Loan Documents (the “ Amendment ”) with AlpineBrook Capital GP I Limited (the “ Lender ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1845459/000121390026051727/0001213900-26-051727-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.